Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
PDE4 inhibitors
10 evidence topics · 6 sources
FDA-approved indication, dosage, and titration: apremilast
Week 16 clinical response in Trials PSOR-1 and PSOR-2: apremilast label
| Endpoint at Week 16, n (%) | PSOR-1 placebo (N = 282) | PSOR-1 OTEZLA 30 mg BID (N = 562) | PSOR-2 placebo (N = 137) | PSOR-2 OTEZLA 30 mg BID (N = 274) |
|---|---|---|---|---|
| PASI-75 | “15 (5.3)” | “186 (33.1)” | “8 (5.8)” | “79 (28.8)” |
| sPGA of clear or almost clear | “11 (3.9)” | “122 (21.7)” | “6 (4.4)” | “56 (20.4)” |
ESTEEM 1: PASI-75 at week 16, maintenance through week 52, and adverse events
“ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to severe plaque psoriasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In all, 844 patients were randomized (n = 282, placebo; n = 562, apremilast).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 16, significantly more patients taking apremilast achieved 75% or greater reduction from baseline Psoriasis Area and Severity Index score (PASI-75) (33.1%) versus placebo (5.3%, P < .0001; primary end point).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most (61.0%) patients rerandomized to apremilast at week 32 achieved PASI-75 at week 52 versus 11.7% rerandomized to placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the placebo-controlled period, 55.7% and 69.3% of patients randomized to placebo and apremilast, respectively, had 1 or more adverse events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ESTEEM 2: PASI 75, PASI 50, and sPGA 0 or 1 at week 16 and common adverse events
“ESTEEM 2 evaluated the efficacy and safety of apremilast 30 mg twice daily for moderate-to-severe plaque psoriasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The modified intention-to-treat population (full analysis set) included 137 placebo and 274 apremilast patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 16, significantly more apremilast patients achieved PASI 75 (28·8%), PASI 50 (55·5%) and static Physician's Global Assessment score of 0 or 1 (20·4%) vs. placebo (5·8%, 19·7%, 4·4%, respectively; P < 0·001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common adverse events were nausea, diarrhoea, nasopharyngitis and upper respiratory tract infection.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adverse reactions through week 16 in adults with moderate to severe plaque psoriasis: apremilast label
| Adverse reaction, n (%) | Placebo (N = 506) | OTEZLA 30 mg BID (N = 920) |
|---|---|---|
| Diarrhea | “32 (6)” | “160 (17)” |
| Nausea | “35 (7)” | “155 (17)” |
| Tension headache | “21 (4)” | “75 (8)” |
| Headache | “19 (4)” | “55 (6)” |
Discontinuation, depression, and weight decrease: apremilast label
Apremilast: guideline recommendation, gastrointestinal adverse effects, and absence of laboratory monitoring
Network meta-analysis: phosphodiesterase-4 inhibitors, serious adverse events and PASI 75 compared with biologics
“Phosphodiesterase‐4 inhibitors had the highest SUCRA at class level in terms of SAEs (versus placebo: RR 0.76, 95% CI 0.47 to 1.23; SUCRA = 70.8)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was evidence of a difference in favour of infliximab, anti‐IL17 agents (ixekizumab, bimekizumab, and secukinumab), and risankizumab compared to ustekinumab, other anti‐TNF‐alpha agents (adalimumab, certolizumab, and etanercept), and synthetic targeted treatments (apremilast and deucravacitinib) in terms of achieving PASI 75.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis: estimated PASI response rates at 10 to 16 weeks for apremilast and dimethyl fumarate
Network meta-analysis design: bayesian analysis of short-term PASI response at 10 to 16 weeks in 60 trials and a traditional meta-analysis at 44 to 60 weeks
“A bayesian network meta-analysis was conducted to estimate short-term PASI response rates; to account for variation across trials, an ordinal model that adjusted for reference arm response was implemented.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The long-term PASI rates were estimated via a traditional meta-analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a network meta-analysis of 60 clinical trials for short-term efficacy, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa had the highest Psoriasis Area and Severity Index response rates at 10 to 16 weeks from baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 60 trials meeting all inclusion criteria were included in the base-case NMA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The base-case analysis included all biologics, apremilast, and dimethyl fumarate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated PASI response rates were summarized using posterior medians and their associated 95% credible intervals (CrIs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote